USTR expresses growing concerns on IP protection in India and other markets

1 May 2014

The Office of the US Trade Representative (USTR) has released its annual “Special 301” Report on the adequacy and effectiveness of US trading partners’ protection and enforcement of intellectual property rights (IPR), highlighting growing concerns with respect to the environment for IPR protection and enforcement in India and other markets.

Other significant elements of the 2014 Special 301 Report include the following:

The Report expresses ongoing, serious concerns about the protection and enforcement of trade secrets with respect to China, and emerging concerns in other markets.
The USTR removes Italy and the Philippines from the Watch List in recognition of their IPR-related accomplishments, and as an indication of support for their commitment to continued progress.
The USTR announces that it will conduct Out-of-Cycle reviews to promote engagement and progress on IPR challenges identified in this year’s reviews of India, Kuwait, Paraguay and Spain.
The USTR has decided not to add Canada to its “Priority Watch” list of countries that fail to sufficiently protect and enforce patent rights.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK